Home » Newsletters » BioWorld Science

BioWorld Science

June 18, 2021

View Archived Issues

PureTech advances its wholly owned pipeline

Phase II results presented for ZYN-002 in children and adolescents with DEE

BriaCell advances personalized immunotherapies for prostate cancer, melanoma and lung cancer

FDA accepts IND for phase I trial of Xilio's XTX-101 in solid tumors

Algernon plans phase I study of AP-188 for stroke

Akaal reports preclinical data on AK-119 in neuropathic pain

Modus collaborates with Imperial College London on clinical study of sevuparin in malaria

Harbour BioMed begins phase I dosing with HBM-4003 in NSCLC

Satsuma reports phase I safety and PK data on STS-101

4SC and NKI collaborate to study neoadjuvant domatinostat in urothelial carcinoma

Amgen synthesizes new fatty acid desaturase 1 inhibitors

Daewoong Pharmaceutical patents JAK3 inhibitors

Aurigene Discovery Technologies presents new CD73 inhibitors

Chinese investigators describe new JAK inhibitors

Alnylam Pharmaceuticals divulges ATXN3-targeting ds-siRNAs

Phase I data for the novel first-in-class anti-SIRPalpha antibody, BI-765063

177Lu-DOTAGA.(SA.FAPi)2 use for thyroid cancer

Viking reports phase I data on TRbeta agonist VK-0214

New basket trial evaluates spartalizumab in tumors with high PD-1 expression levels

Reversible BTK inhibitors from Hyperway described

HSV-targeting compound affects latent infection

Anji licenses rights to MCL1 inhibitor program from Broad Institute

Histopathology data reported for TATX-03a in SARS-CoV-2 challenged hamsters

Kite and ShoreLine Biosciences partner on allogeneic cell therapies for hematologic malignancies

Qpex opens phase I study of QPX-9003 for infections caused by drug-resistant Gram-negative pathogens

Evaluation of DAN-222 alone or in combination with PARP inhibitor in models of breast cancer

Increased PARP activity in PBLs could predict prostate cancer susceptibility

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...